U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C26H22BrN5O2
Molecular Weight 516.389
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of 4-[[(7-Bromo-3,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]-2-propyn-1-ylamino]-N-(3-pyridinylmethyl)benzamide

SMILES

CC1=NC2=C(C=C(CN(CC#C)C3=CC=C(C=C3)C(=O)NCC4=CN=CC=C4)C(Br)=C2)C(=O)N1

InChI

InChIKey=SHNBLWMBWXIKMR-UHFFFAOYSA-N
InChI=1S/C26H22BrN5O2/c1-3-11-32(16-20-12-22-24(13-23(20)27)30-17(2)31-26(22)34)21-8-6-19(7-9-21)25(33)29-15-18-5-4-10-28-14-18/h1,4-10,12-14H,11,15-16H2,2H3,(H,29,33)(H,30,31,34)

HIDE SMILES / InChI
Molecular Formula C26H22BrN5O2
Molecular Weight 516.389
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

CB30865 (ZM242421) is a potent inhibitor of Nampt, an enzyme present in the NAD biosynthetic pathway. CB30865 is highly potent against a variety of human tumour cell lines.

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Nicotinamide phosphoribosyltransferase
8
Target ID: P43490
Gene ID: 10135.0
Gene Symbol: NAMPT
Target Organism: Homo sapiens (Human)
Inhibitor
8504
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Basic research
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Chemical proteomics identifies Nampt as the target of CB30865, an orphan cytotoxic compound.
2010-06-25
Cell cycle effects of CB30865, a lipophilic quinazoline-based analogue of the antifolate thymidylate synthase inhibitor ICI 198583 with an undefined mechanism of action.
1998-09-01
Patents

Patents

WO 2000050417 A1
1

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Unknown
In Vitro Use Guide
Growth inhibitory potency was determined after continuous exposure of cells to CB30865 for 48 h (L1210), 72 h (W1L2), or 96 h (CH1) followed by Coulter Counting (L1210 and W1L2) or 3-[4,5-dimethylthiazol-2yl]-2,5-diphenyltetrazolium bromide (MTT) assay. CB30865 inhibited tumor growth with IC50 values in the 1-10 nM range.
Substance Class Chemical
Created
by admin
on Wed Apr 02 18:25:09 GMT 2025
Edited
by admin
on Wed Apr 02 18:25:09 GMT 2025
Record UNII
QH8386GD3S
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
4-[[(7-Bromo-3,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]-2-propyn-1-ylamino]-N-(3-pyridinylmethyl)benzamide
Systematic Name English
4-((7-Bromanyl-2-methyl-4-oxidanylidene-3H-quinazolin-6-yl)methyl-prop-2-ynyl-amino)-N-(pyridin-3-ylmethyl)benzamide
Preferred Name English
Benzamide, 4-[[(7-bromo-3,4-dihydro-2-methyl-4-oxo-6-quinazolinyl)methyl]-2-propyn-1-ylamino]-N-(3-pyridinylmethyl)-
Systematic Name English
Code System Code Type Description
EPA CompTox
DTXSID70432117
Created by admin on Wed Apr 02 18:25:09 GMT 2025 , Edited by admin on Wed Apr 02 18:25:09 GMT 2025
PRIMARY
PUBCHEM
135528987
Created by admin on Wed Apr 02 18:25:09 GMT 2025 , Edited by admin on Wed Apr 02 18:25:09 GMT 2025
PRIMARY
CAS
206275-15-2
Created by admin on Wed Apr 02 18:25:09 GMT 2025 , Edited by admin on Wed Apr 02 18:25:09 GMT 2025
PRIMARY
FDA UNII
QH8386GD3S
Created by admin on Wed Apr 02 18:25:09 GMT 2025 , Edited by admin on Wed Apr 02 18:25:09 GMT 2025
PRIMARY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966